MS may decrease all-cause survival among women with breast cancer Disclosures:
Marrie reports receiving research funding from CIHR, CMSC, Crohn’s and Colitis Canada, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, National Multiple Sclerosis Society, Research Manitoba and the Arthritis Foundation and support from the Waugh Family Chair in Multiple Sclerosis. Please see the study for all other authors’ relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Subscribe
ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
PRESS RELEASE FROM SERMO
Global Efforts to Stop the Spread of COVID-19 Undermined by Vaccine Side Effect Concerns Posted May 20, 2021
Global Efforts to Stop the Spread of COVID-19 Undermined by Vaccine Side Effect Concerns
Insights from Sermo’s COVID-19 Real Time Barometer Survey point toward disease becoming endemic and need for more effective patient education
New York, NY – May, 20 2021 - As the rate of people receiving COVID-19 vaccinations has slowed, a new survey of physicians has revealed that doctors are working hard to combat vaccine hesitancy, even among those who have already received their first dose. More than 72% of physicians surveyed said that patients continue to voice concerns over vaccine side effects. Still, others have reported ongoing misinformation discouraging people from getting vaccines. In addition, close to 30% of physicians reported encountering patients who have skipped their second dose due to unpleasant side ef
Decreased COVID Antibody Response in MS Patients Taking Ocrelizumab medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
by Tyler Durden
Wednesday, May 12, 2021 - 04:15 AM
The best way to decrease the risk of Alzheimer s disease could be a Mediterranean diet that is rich in fish, vegetables, and olive oil, according to a new study.
The research, titled Mediterranean Diet, Alzheimer Disease Biomarkers and Brain Atrophy in Old Age, was published in the online issue of Neurology, the medical journal of the American Academy of Neurology, and found a Mediterranean rich diet may protect the brain from protein build-up and shrinkage that can lead to the debilitating neurological disease.
The study examines abnormal proteins called amyloid and tau. The amyloid-beta precursor protein plays a vital role in neural growth and repair. However, later in life, a corrupted version can destroy nerve cells, leading to memory loss, while tau is a protein that forms into a tangle. Both are found in the brains of people with Alzheimer s disease but may also be found in the brains of older adults with heal
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Strongbridge Biopharma plc Reports First Quarter 2021 Financial Results and Provides Corporate .
Strongbridge Biopharma plcMay 12, 2021 GMT
~ Reports KEVEYIS
®
(dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter of 2020 ~
~ Reiterates Full-Year 2021 KEVEYIS
(dichlorphenamide) Revenue Guidance of Approximately $34 Million to $36 Million ~
~ Awaiting Day 74 Letter from U.S. Food & Drug Administration (FDA) for the Company’s New Drug Application (NDA) Submission for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome ~
~ Receives Notification from United States Patent and Trademark Office that it has Entered a Notice of Allowance Covering a Method of Treating Patients with Cushing’s Syndrome with RECORLEV® (levoketoconazole) ~